GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (NAS:PHAR) » Definitions » Capex-to-Operating-Cash-Flow

PHAR (Pharming Group) Capex-to-Operating-Cash-Flow : 1.24 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Pharming Group Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Pharming Group's Capital Expenditure for the three months ended in Mar. 2025 was $-0.29 Mil. Its Cash Flow from Operations for the three months ended in Mar. 2025 was $0.23 Mil.

Hence, Pharming Group's Capex-to-Operating-Cash-Flow for the three months ended in Mar. 2025 was 1.24.


Pharming Group Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Pharming Group's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Capex-to-Operating-Cash-Flow Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.44 0.09 - -

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 0.04 0.02 1.24

Competitive Comparison of Pharming Group's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Pharming Group's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Pharming Group's Capex-to-Operating-Cash-Flow falls into.


;
;

Pharming Group Capex-to-Operating-Cash-Flow Calculation

Pharming Group's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2024 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.796) / -1.795
=N/A

Pharming Group's Capex-to-Operating-Cash-Flow for the quarter that ended in Mar. 2025 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.288) / 0.232
=1.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharming Group  (NAS:PHAR) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Pharming Group Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Pharming Group's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Industry
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

From GuruFocus

Q4 2024 Pharming Group NV Earnings Call Transcript

By GuruFocus News 03-14-2025

Q3 2024 Pharming Group NV Earnings Call Transcript

By GuruFocus News 10-25-2024

Q1 2024 Pharming Group NV Earnings Call Transcript

By GuruFocus Research 05-09-2024

Q1 2023 Pharming Group NV Earnings Call Transcript

By GuruFocus Research 02-08-2024

Pharming Group NV Annual Shareholders Meeting Transcript

By GuruFocus Research 02-08-2024

Q2 2021 Pharming Group NV Earnings Call Transcript

By GuruFocus Research 02-08-2024

Q4 2023 Pharming Group NV Earnings Call Transcript

By GuruFocus Research 03-15-2024